Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

Abstract: A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

Abstract: The present invention provides a method and a diagnostic kit for diagnosing the presence of Parkinson's disease in a human subject. The method includes the steps of: (1) extracting RNA molecules from a blood sample of the human subject to define a test sample; (2) measuring the amount of each RNA molecule having Sequence ID Nos. 1-14 in the test sample; (3) comparing the amount of each of the RNA molecules having Sequence ID Nos. 1-14 to the amount of RNA molecules having Sequence ID Nos. 1-14 present in a control sample to determine how many of the RNA molecules of Sequence ID Nos. 1-14 are present in a significant amount in the test sample greater or less than in the control sample to define a number of biomarkers; and (4) diagnosing the presence of Parkinson's disease in the human subject if the number of biomarkers is equal to or greater than five.

Abstract: A system is provided for monitoring whether a user is wearing and/or using a tagged device such as prescribed footwear, a walking aid, a brace or other orthotics. The system may detect whether the user is using a tagged device and can, in some embodiments, alert the user or the user's caregivers if the user ambulates without using the tagged device.

Abstract: The present invention provides a kit for measuring the content of micro-RNA in a human blood sample including a blood collection tube containing at least 1 ?g NaF and 0.8 ?g KOx; and providing a set of instructions for collecting a human blood sample in the blood collection tube.

Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

Abstract: The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a ?-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same.

Abstract: The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).

Abstract: The present invention relates generally to the use of ?-glutamyl antioxidants, particularly ?-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The ?-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).

Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Abstract: The present invention provides a method and a diagnostic kit for diagnosing the presence of Parkinson's disease in a human subject. The method includes the steps of: (1) extracting RNA molecules from a blood sample of the human subject to define a test sample; (2) measuring the amount of each RNA molecule having Sequence ID Nos. 1-14 in the test sample; (3) comparing the amount of each of the RNA molecules having Sequence ID Nos. 1-14 to the amount of RNA molecules having Sequence ID Nos. 1-14 present in a control sample to determine how many of the RNA molecules of Sequence ID Nos. 1-14 are present in a significant amount in the test sample greater or less than in the control sample to define a number of biomarkers; and (4) diagnosing the presence of Parkinson's disease in the human subject if the number of biomarkers is equal to or greater than five.

Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

Abstract: The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a Leishmania transfected for expressing a cDNA sequence for encoding the protein vaccination candidate, and the Leishmania containing a photosensitizer.

Abstract: The present invention relates generally to the use of circulating cytochrome c as a biomarker of reperfusion injury that results from whole body ischemia. Circulating levels of cytochrome c can be used as predictor of survival rates and to assess the effects of interventions aimed at ameliorating mitochondrial injury during reperfusion. Whole body ischemia may be the result of cardiac arrest or from other hemodynamic crises, such as hemorrhagic shock.

Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes.

Abstract: The present invention provides an extremity stress reducing modality for a human subject having an extremity, the extremity having an uninjured portion and an injured portion. The modality includes: (1) a frame having a connecting member for removably connecting the frame to an extremity of a human subject; (2) a support member on the frame for engaging the uninjured portion but not the injured portion; and (3) an attachment member on the frame for attaching the frame to a portion of a moveable resistance mechanism.

Abstract: The present invention relates generally to the use of ?-glutamyl antioxidants, particularly ?-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The ?-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).